177 related articles for article (PubMed ID: 22960341)
1. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.
Eissa S; Badr S; Elhamid SA; Helmy AS; Nour M; Esmat M
Dis Markers; 2013; 34(1):57-62. PubMed ID: 22960341
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic efficacy of urinary survivin and hyaluronidase mRNA as urine markers in patients with bladder cancer.
Eissa S; Badr S; Barakat M; Zaghloul AS; Mohanad M
Clin Lab; 2013; 59(7-8):893-900. PubMed ID: 24133921
[TBL] [Abstract][Full Text] [Related]
3. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
4. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.
Pu XY; Wang ZP; Chen YR; Wang XH; Wu YL; Wang HP
J Cancer Res Clin Oncol; 2008 Jun; 134(6):659-65. PubMed ID: 18026991
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of urinary molecular markers in bladder cancer.
Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
Roy R; Louis G; Loughlin KR; Wiederschain D; Kilroy SM; Lamb CC; Zurakowski D; Moses MA
Clin Cancer Res; 2008 Oct; 14(20):6610-7. PubMed ID: 18927302
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of urine-based survivin mRNA test using reverse transcription-polymerase chain reaction for bladder cancer: a systematic review.
Xia Y; Liu YL; Yang KH; Chen W
Chin J Cancer; 2010 Apr; 29(4):441-6. PubMed ID: 20346223
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.
Eissa S; Shabayek MI; Ismail MF; El-Allawy RM; Hamdy MA
IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180
[TBL] [Abstract][Full Text] [Related]
10. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
[TBL] [Abstract][Full Text] [Related]
11. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer.
Fouad H; Salem H; Ellakwa DE; Abdel-Hamid M
J Biochem Mol Toxicol; 2019 Apr; 33(4):e22275. PubMed ID: 30548095
[TBL] [Abstract][Full Text] [Related]
12. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
13. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Urology; 2001 Apr; 57(4):675-9. PubMed ID: 11306379
[TBL] [Abstract][Full Text] [Related]
14. Urine detection of survivin and diagnosis of bladder cancer.
Smith SD; Wheeler MA; Plescia J; Colberg JW; Weiss RM; Altieri DC
JAMA; 2001 Jan; 285(3):324-8. PubMed ID: 11176843
[TBL] [Abstract][Full Text] [Related]
15. [Value of combined detection of urinary Livin and Survivin mRNA expression in the early diagnosis of bladder cancer].
Jiang LL; Xie MM; Wang XR; Zhao Y; Wang ZJ
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3520-2. PubMed ID: 24521893
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.
Weikert S; Christoph F; Schrader M; Krause H; Miller K; Müller M
Int J Cancer; 2005 Aug; 116(1):100-4. PubMed ID: 15761870
[TBL] [Abstract][Full Text] [Related]
18. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas.
Pina-Cabral L; Santos L; Mesquita B; Amaro T; Magalhães S; Criado B
Clin Transl Oncol; 2007 Nov; 9(11):731-6. PubMed ID: 18055328
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic role of survivin in urinary bladder cancer.
Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
Eissa S; Zohny SF; Swellam M; Mahmoud MH; El-Zayat TM; Salem AM
Clin Biochem; 2008 Nov; 41(16-17):1335-41. PubMed ID: 18804101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
